Regeneron

YTD

ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.

CEO

Leonard S. Schleifer

CEOLeonard S. Schleifer

Employees

15,106

Employees15,106

Headquarters

Tarrytown, New York

HeadquartersTarrytown, New York

Founded

1988

Founded1988

Employees

15,106

Employees15,106

REGN Key Statistics

Market cap

63.46B

Market cap63.46B

Price-Earnings ratio

14.75

Price-Earnings ratio14.75

Dividend yield

0.45%

Dividend yield0.45%

Average volume

918.04K

Average volume918.04K

High today

$600.00

High today$600.00

Low today

$583.92

Low today$583.92

Open price

$590.39

Open price$590.39

Volume

1.27M

Volume1.27M

52 Week high

$1,165.85

52 Week high$1,165.85

52 Week low

$476.49

52 Week low$476.49

REGN News

Simply Wall St 1d

Regeneron Pharmaceuticals: Evaluating Valuation Following Breakthrough Phase 3 Allergy Drug Results

If you’re wondering whether now is the time to take a closer look at Regeneron Pharmaceuticals (REGN), you’re not alone. The company’s recent announcement of pr...

Benzinga 1d

Regeneron Touts Positive Data From Phase 3 Study In Patients With Ultra-Rare Genetic Disorder

Regeneron Pharmaceuticals Inc. REGN reported positive results from its Phase 3 OPTIMA trial of garetosmab in adults with fibrodysplasia ossificans progressiva (...

TipRanks 1d

Regeneron announces primary endpoint met in Phase 3 OPTIMA trial

Regeneron (REGN) Pharmaceuticals announced the primary endpoint was met in the Phase 3 OPTIMA trial investigating garetosmab in adults with fibrodysplasia ossif...

Analyst ratings

79%

of 28 ratings

Buy

78.6%

Hold

17.9%

Sell

3.6%

More REGN News

Simply Wall St 5d

Does Regeneron Offer Value After Shares Slide 21.7% Year to Date in 2025?

If you have ever wondered whether now is the right time to buy, hold, or reconsider Regeneron Pharmaceuticals, you are definitely not alone. The company has bee...

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.